(IN BRIEF) Boehringer Ingelheim has launched EURICAN® L4, a new vaccine designed to protect dogs from leptospirosis, a potentially fatal disease spread through contaminated soil and water. Available in France and expanding across Europe in 2025, the vaccine targets four … Read the full press release
(IN BRIEF) Boehringer Ingelheim has launched VETMEDIN® Solution, the first FDA-approved liquid treatment for congestive heart failure (CHF) in dogs caused by myxomatous mitral valve disease (MMVD) or dilated cardiomyopathy (DCM). The solution provides a convenient, twice-daily alternative to tablets, … Read the full press release
(IN BRIEF) Boehringer Ingelheim and the WHO Foundation have partnered to promote equitable healthcare access and suicide prevention, with a focus on vulnerable communities in the Americas. Boehringer Ingelheim pledged $5 million to support WHO’s 2025–2028 General Program of Work … Read the full press release
Posted in Business, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Society
Tagged Anil Soni, Boehringer Ingelheim, Global Healthcare Access, Médard Schoenmaeckers, mental health, partnership, society, Suicide Prevention Efforts, WHO Foundation
(IN BRIEF) Boehringer Ingelheim and CDR-Life have reported positive results from the Phase I trial of BI 771716, an investigational treatment for geographic atrophy (GA), a severe form of age-related macular degeneration. The antibody fragment met its primary safety endpoints, … Read the full press release
(IN BRIEF) In a significant stride towards combating metabolic dysfunction-associated steatohepatitis (MASH), Boehringer Ingelheim unveils groundbreaking results from a Phase II trial sub-analysis of survodutide. Demonstrating impressive efficacy, up to 64.5% of adults with moderate to advanced fibrosis stages F2 … Read the full press release
(IN BRIEF) A recent study commissioned by Boehringer Ingelheim, conducted across eight G20 countries, sheds light on the challenges obstructing access to mental health care worldwide. The analysis reveals pervasive stigma, a shortage of mental health professionals, and inconsistent service … Read the full press release
(IN BRIEF) Boehringer Ingelheim and OSE Immunotherapeutics announce a significant expansion of their partnership, introducing two novel projects to develop pioneering treatments alongside their ongoing anti-SIRPα immuno-oncology initiatives. The expansion includes broadening therapeutic evaluations to encompass cardiovascular-renal-metabolic (CRM) diseases and … Read the full press release
Posted in Business, Education, Environment, Financial, France, Germany, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged Boehringer Ingelheim, Clive R. Wood, Disease Treatment, Nicolas Poirier, OSE Immunotherapeutics, partnership, sustainability
(IN BRIEF) The Conference Forum announced the launch of the 8th annual Patients as Partners® Europe meeting, scheduled for May 14-15, 2024, at Plaisterers’ Hall in London, England. This event brings together pharma R&D and patient advocacy to discuss patient … Read the full press release
Posted in Healthcare, Marketing, Pharma & Biotech, United Kingdom
Tagged 8th annual Patients as Partners® Europe, AbbVie, Anders Lassen, Andrew Garvey, Annie Gilbert, Astellas, AstraZeneca, Biotech, Boehringer Ingelheim, clinical operations, clinical research, clinical trials, Conference, David James, decentralized clinical trials, Derek Stewart, diversifying clinical trials, diversity, drug development, England, GSK, Health Equity, inclusivity, inclusivity in clinical research, Ipsen, LGBTQ+ oncology, Lisa Kerr, London, Lundbeck, Novartis, Novo Nordisk, Oleksandr Gorbenko, Parexel, Patient Advocacy, patient engagment, patient experience mapping, Patrick Gallogly, Pfizer, pharma, Plaisterers’ Hall, Prostate Cancer Research, Rosamund Round, Sanofi, Sarah Zenner Dolan, Stephen Head, The Conference Forum, Valerie Bowling, Victoria DiBiaso, , Alfred Samuel
(IN BRIEF) Boehringer Ingelheim and Sosei Group Corporation (Sosei Heptares) have unveiled a global collaboration and exclusive option-to-license agreement aimed at advancing the development and commercialization of Sosei Heptares’ portfolio of first-in-class GPR52 agonists. The focus of this collaboration lies … Read the full press release
Posted in Business, Education, Environment, Financial, Germany, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged Boehringer Ingelheim, GPR52 agonists, Hugh Marston, Matt Barnes, mental health, partnership, schizophrenia, Sosei Heptares, sustainability, treatment
(IN BRIEF) Boehringer Ingelheim has reported compelling results from its Phase II trial of Survodutide, a novel glucagon/GLP-1 receptor dual agonist, indicating its potential to become a leading treatment for Metabolic Dysfunction-Associated Steatohepatitis (MASH). In the trial, up to 83.0% … Read the full press release
Posted in Business, Education, Financial, Germany, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged Boehringer Ingelheim, Carinne Brouillon, Dr. Arun Sanyal, MASH, Phase II Trial, Survodutide, treatment
(IN BRIEF) Boehringer Ingelheim has been honored by the Top Employers Institute with a “Global Top Employer” certification for the fourth consecutive year, distinguishing it as one of only 17 globally certified companies. The recognition is attributed to the company’s … Read the full press release
Posted in Awards, Business, Germany, Industrial, Management, News, Pharma & Biotech
Tagged Awards, Boehringer Ingelheim, Employee Development, Global Top Employer, Sven Sommerlatte, wellbeing
(IN BRIEF) Boehringer Ingelheim and IBM have formed a partnership to expedite the discovery of novel candidate antibodies for therapeutic purposes. Boehringer will utilize IBM’s foundation model technologies, combining them with their proprietary data to enhance the antibody discovery process. … Read the full press release
(IN BRIEF) Pharmaceutical company Boehringer Ingelheim has declared its intention to move forward with survodutide, a dual agonist targeting the glucagon/GLP-1 receptors, into three Phase III clinical trials for individuals suffering from overweight or obesity. This decision stems from promising … Read the full press release
(IN BRIEF) Boehringer Ingelheim has begun construction on a new Chemical Innovation Plant at its headquarters in Ingelheim, Germany. The €285 million investment will develop manufacturing processes for active pharmaceutical ingredients and produce drugs for clinical trial phases, enabling Boehringer … Read the full press release
(IN BRIEF) The Conference Forum has announced that the 7th annual European Patients as Partners® in Clinical Research conference will take place in London on June 12-13, 2023. The event will focus on achieving greater representation in clinical research, building … Read the full press release
Posted in Government, Healthcare, News, Non Profit, Pharma & Biotech, United Kingdom
Tagged 7th annual European Patients as Partners®, biotechnology, Boehringer Ingelheim, Center for BME Health, clinical development, clinical research, Clinical Research conference, clinical trials, Community Engagement, CSL Behring, Deirdre BeVard, Diversity in Clinical Research, drug development, government, Health Equity, Healthcare, Hospital, Lundbeck, Medicine Development, Medicine Lifestyle, Medicines Development, Novartis, Patient Advocacy, Patient Centricity, Patient Communities, patient engagement, Patient Perspective, Patient Recruitment, Patient Retention, Patient Voice, Patients as Partners, Pharmaceutical, research and development, Sanofi, The Conference Forum, Thistle Hotel Marble Arch, Valerie Bowling
(PRESS RELEASE) INGELHEIM, 17-Jan-2023 — /EuropaWire/ — Boehringer Ingelheim, one of the world’s leading research-driven pharmaceutical companies with 130 years of experience, has announced it has been named a “Global Top Employer” for the third year in a row by the … Read the full press release
Posted in Awards, Germany, Healthcare, Management, Pharma & Biotech
Tagged Boehringer Ingelheim, Corporate World, counselors, Dr Sven Sommerlatte, employee healthcare, Employee Wellbeing, Global Top Employer, mental health, outstanding employer benefits, pharmaceutical company, positive work environment, prestigious honor, psychologists, Top Employers Institute, wellbeing, work life balance
(COMUNICADO DE PRENSA) INGELHEIM, 17-Jan-2023 — /EuropaWire/ — Boehringer Ingelheim, una de las principales compañías farmacéuticas del mundo impulsadas por la investigación con 130 años de experiencia, ha anunciado que ha sido nombrada “Global Top Employer” por tercer año consecutivo por … Read the full press release
Posted in Awards, Germany, Healthcare, Management, Pharma & Biotech
Tagged ambiente de trabajo positivo, atención médica para empleados, beneficios sobresalientes para empleadores, bienestar, Bienestar de los empleados, Boehringer Ingelheim, compañía farmacéutica, consejeros, Corporate World, Dr. Sven Sommerlatte, equilibrio entre la vida personal y laboral, Global Top Employer, honor prestigioso, psicólogos, salud mental, Top Employers Institute
Metacam® 0.5mg/ml Oral Suspension for Cats is now also approved in Europe for alleviation of mild to moderate post-operative pain associated with soft tissue surgery in guinea-pigs True market need to provide relief after painful procedures and surgeries Boehringer Ingelheim is … Read the full press release
Posted in Germany, Healthcare, Pharma & Biotech
Tagged analgesic, anti-inflammatory, Boehringer Ingelheim, Europe, guinea pigs, medicine, Metacam®, Shawn Hooker, Veterinary Medicines
The programme was set up by the International Society of Feline Medicine (ISFM), the veterinary division of the charity International Cat Care (ICC) Boehringer Ingelheim will promote the programme and develop informational tools and services to grow veterinarians’ and cat … Read the full press release
Posted in Germany, Healthcare, Pharma & Biotech
Tagged Boehringer Ingelheim, Cat Friendly Clinic programme, Shawn Hooker
61% of IPF patients are worried or extremely worried about experiencing an acute IPF exacerbation1 Survey underlines the importance of appropriate support and coping mechanisms for patients living with IPF1 Healthcare teams emphasise the need of a strong support network … Read the full press release
Posted in Germany, Healthcare, Pharma & Biotech, Society
Tagged Boehringer Ingelheim, Dr. Marlies Wijsenbeek, idiopathic pulmonary fibrosis, IPF, survey
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?